Real-Time Live-Cell Observation Platform Could Transform Cancer Drug Discovery and Precision Medicine
Key Insights
A novel platform enabling continuous observation of living cells could reshape drug discovery by revealing previously unobservable cellular dynamics, according to experts.
Dr. Shyam Aggarwal of Sir Ganga Ram Hospital emphasized that real-time technologies can fast-track detection of subtle biochemical changes and identify promising therapies more efficiently during preclinical research.
Precigenetics (search) CEO Parmita Mishra noted that moving beyond biological "autopsies" to continuous cellular monitoring has implications across oncology, immunology, neuroscience, rare diseases, and regenerative medicine.
A platform that enables researchers to observe living cells on a continuous basis could fundamentally transform drug discovery, reshape cancer (search) research, and advance precision medicine, according to experts speaking on the subject. The technology addresses a longstanding bottleneck in pharmaceutical R&D: the inability of conventional laboratory models to fully capture the complexity and dynamic behavior of living cells.
Dr. Shyam Aggarwal, Chairperson of the Department of Medical Oncology at Sir Ganga Ram Hospital, New Delhi, stated that real-time observation technologies could help researchers better understand how cells respond to candidate drugs. "It could help fast track detection of subtle biochemical changes, and identify promising therapies more efficiently during preclinical research," Aggarwal said.
The Limitations of Conventional Approaches
Cancer (search) drug development remains one of the most difficult areas of pharmaceutical research. Industry studies have consistently shown that the vast majority of oncology drug candidates entering clinical development ultimately fail before reaching patients. Scientists increasingly attribute many of these failures to the inability of existing laboratory models to fully capture the complexity and dynamic behavior of living cells.
Unlike conventional laboratory techniques that often require cells to be stained, fixed, or broken apart before analysis, the new platform seeks to monitor living biology continuously. This allows scientists to study cellular behavior over time rather than relying on isolated end-point measurements.
From Biological 'Autopsies' to Living Insights
Parmita Mishra, Founder and CEO of San Francisco-based Precigenetics (search), which runs a platform to generate real-time biochemical information from living cells, articulated the paradigm shift. "When researchers continuously measure how cells behave instead of relying on biological 'autopsies,' they may uncover insights that were previously impossible to observe," Mishra said.
Mishra further emphasized the broad applicability of the approach: "That has implications far beyond cancer (search), extending into immunology, neuroscience, rare diseases and regenerative medicine."
Precision Oncology and Personalized Medicine
Aggarwal also highlighted the convergence of real-time cellular observation with other advances in precision oncology. "Understanding precision oncology with comprehensive genome profiling (CGP) and minimal residual disease detection (MRD) will help physicians improve targeted personalised medicine for cancer (search) patients," he noted.
The Growing Cancer (search) Burden
The urgency for improved drug discovery tools is underscored by the rising global and national cancer (search) burden. India reported an estimated 1.4 million new cancer cases in 2022, according to data from the International Agency for Research on Cancer (IARC). The Indian Council of Medical Research (ICMR) has projected that the country's cancer burden will continue to rise over the coming decade, reinforcing the need for more efficient and predictive preclinical platforms that can accelerate the development of effective oncology therapies.